Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The researchers reported that a novel family of butyric acid prodrugs, including AN-9 and AN-10, showed potential for anticancer activity, hemoglobin expression induction, and hair follicle protection, with AN-9 in phase II trials.

This study identified orally available itaconate derivatives that improve cellular permeability and bioavailability, with specific POC-based prodrugs showing significant inhibition of inflammatory cytokines in human epidermal keratinocytes and favorable oral pharmacokinetics, highlighting their potential for treating systemic and skin disorders.

This review discusses recent advances in monophosphate prodrug strategies for HCV drug discovery, aiming to enhance oral absorption and stability, and reports no new clinical results.

This study reports that RU 58841-myristate, a new antiandrogen prodrug formulated with solid lipid nanoparticles, shows potential for targeting hair follicles in preclinical laboratory settings.

This review reports that pharmacogenomic variations in the SULT1A1 enzyme significantly influence the response to minoxidil treatment for alopecia, suggesting personalized therapeutic strategies could improve efficacy while emerging pharmaceutical technologies aim to optimize oral minoxidil's absorption and minimize side effects.

This article discusses the development of targeted prodrug conjugates aimed at selectively attacking cancer cells while avoiding healthy ones, but reports no experimental results yet.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

This study reported that a modified version of Thymosin beta 4, called PEG-rTβ4, demonstrated potential as a treatment for acute myocardial infarction by improving cardiac function and reducing cell death via specific biochemical pathways, suggesting its promise in drug development efforts.

This study found that ketorolac tert-butyl ester enhances skin permeation and follicular absorption compared to ketorolac, highlighting the role of lipophilicity and solubility in prodrug design.

This review discusses the role of skin enzymes in drug metabolism and emphasizes the need for models assessing enzyme activity to evaluate the safety and bioequivalence of topical generic drugs, highlighting efforts to standardize testing protocols for transdermal products.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.

This paper reviews the development of transdermal drug delivery systems for skin diseases, from first to fourth generation, and highlights ongoing challenges and the importance of clinical trials, but provides no new clinical results.

This study introduced hydrogel microneedles loaded with palladium nanoparticles, which utilize the inherent cytotoxicity of polyethyleneimine to enhance the effectiveness of doxorubicin in treating melanoma, achieving a tumor inhibition rate of up to 98% in a murine model.

This article reviews the mechanisms and uses of minoxidil for hypertension and androgenetic alopecia, without presenting new clinical findings.

This article reviews various strategies, primarily developed by the Turin University Pharmaceutical Technology group, for increasing entrapment efficiency of hydrophilic molecules in nanoparticulate systems and reports no clinical results.

This article discusses the need for rational strategies in developing hair loss drugs targeting specific events in hair follicle cycling, reporting no clinical findings but emphasizing the importance of understanding molecular controls.

This review discusses the development and potential therapeutic effects of nitroxide small molecule agents for age-related macular degeneration and cardiovascular disease, but reports no new clinical results.

In this study, the safety profile of the prodrug CAP7.1 was found to be similar to other topoisomerase inhibitors, with myelosuppression as the main dose-limiting toxicity.

This review discusses the synthesis and biological activities of jasmonates, highlighting their potential as drugs and prodrugs, but reports no new clinical results; further research and trials are anticipated.

This review highlights how integrating medicinal chemistry with delivery science could transform the limitations of PROTACs—such as poor solubility and low cell permeability—into strengths, potentially advancing these compounds from experimental stages to clinical applications by optimizing their delivery and enhancing therapeutic efficacy.

In this study, a nanoparticle system codelivering diphenylcyclopropenone and rapamycin successfully induced immune tolerance and promoted hair regrowth in a mouse model of alopecia areata, offering a promising new therapeutic strategy for this autoimmune condition.

This study reported the development of pH-responsive nanoparticles that effectively deliver vancomycin in a controlled manner, demonstrated enhanced antibacterial activity, and showed promise for clinical applications by targeting bacterial infection sites with programmable drug release.

This review highlights recent advancements in using nanotechnology to improve the function and delivery of PROTAC drugs, despite existing challenges like low solubility and poor permeability, aiming to enhance their potential in disease treatment.

This review discusses the mechanisms of platinum-induced peripheral neuropathy related to reactive oxygen species and explores potential antioxidant therapies and nanotechnology approaches, but reports no new clinical results.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

This review explores advancements in cytokine engineering for regenerative medicine, highlighting the development of modified cytokines with enhanced stability and tissue-targeting, potentially improving treatments for chronic wounds and fibrotic diseases by promoting tissue healing and minimizing inflammation, while adapting concepts from cancer immunotherapy.

This review discusses the advancements needed for gene therapy to become commonly used in dermatology and reports no new clinical results.

This source discusses the growing trend of drug repurposing, a strategy that seeks new uses for existing drugs to overcome challenges like lengthy timelines and high costs in the traditional drug development process.

This study outlines the potential of drug repurposing to discover new uses for existing medications, emphasizing its cost-effectiveness, efficiency, and ability to address rare diseases by targeting novel biological mechanisms and relying on established safety profiles.

This article discusses drug repurposing as a strategy to find new uses for existing medications, highlighting its potential benefits like faster development and lower costs, while also addressing challenges such as drug specificity, ethical concerns, and regulatory issues.